Bioventus Inc.
BVS
$9.15
-$0.36-3.79%
| 12/31/2024 | 09/28/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.56% | -8.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.56% | -8.10% | |||
| Cost of Revenue | 12.27% | -4.55% | |||
| Gross Profit | 9.73% | -9.73% | |||
| SG&A Expenses | 6.78% | -1.51% | |||
| Depreciation & Amortization | -14.38% | 0.05% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.71% | -2.64% | |||
| Operating Income | 67.38% | -56.63% | |||
| Income Before Tax | 104.80% | 87.75% | |||
| Income Tax Expenses | -6.62% | 108.03% | |||
| Earnings from Continuing Operations | 94.13% | 83.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -72.86% | -92.65% | |||
| Net Income | 96.77% | 79.89% | |||
| EBIT | 67.38% | -56.63% | |||
| EBITDA | -15.96% | -33.39% | |||
| EPS Basic | 96.75% | 80.27% | |||
| Normalized Basic EPS | 373.81% | -107.09% | |||
| EPS Diluted | 96.75% | 80.27% | |||
| Normalized Diluted EPS | 373.81% | -107.09% | |||
| Average Basic Shares Outstanding | 0.30% | 1.88% | |||
| Average Diluted Shares Outstanding | 0.30% | 1.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
